Almost same cost of revenues? Not bad?
Steve is kicking ass!

Don’t forget about the interview today with Eli on YouTube. I don’t have the link but maybe some else can post it here. Good luck to us all. INTV is about to be recognized!

Sorry I just re read the post. My bad. Not sure what the new miners are capable of. I think ETH but I don’t know jack sheet.

Steve has mentioned that INTV currently mines BTC, ETH, and I can’t remember if LTC is one.

Raise your hand if you grabbed those dips today.

I did!!!!

I have a good feeling that next week there will be some happy people around here.

Probably be best if the trader would just shout out “dam it Susan” and not post anything at all, unless there is some legitimacy to their claim.
INTV will have our day soon where everyone is all kiddy and happy.
$INTV

Agreed! I’m looking forward to it!

Nice job.
Wish I had some more cheese. I added 50 shares to my stack. Haha. But the way I see it is when this hits $10.00 that $20 dollars will turn into $500.
Next week I will have some more mullah!

I totally want ONCI to succeed. I have little kids and want distracted driving to be dealt with. But on this ticker I was buying into the idea of what Steve was promising. I lost a lot of money.
Am I mad? Yes and No.
I am mad because we were lied too.

Mad at myself for loosing money and thinking the PPS would rise again.

I don’t bash stocks or pump them.
Some of us have been here before 2016/2017. And it’s ok if people are upset.
They are telling their story. It’s hard for some of us who have been around for awhile to have new people come in a state all these great thing Steve is doing etc when we have been on the other end of the things Steve has not followed through with.

BDP
How goes it?

SEC is cracking down.
OCMillionaire just got busted.

https://www.sec.gov/news/press-release/2021-46

Steve you are next. I remember Steve telling us that be safe mobile was going to Walgreens and Target. And we were all buying houses in 2019. I trusted him and the idea of distracted driving. He lied. Over and over again. I lost around $40K.
Hope he gets time in jail.

I was told that the News Runway is serious!
Good things coming!
$INTV

You have to ask AP17. I’m not a Mod

He already confessed to making the mistake. See his previous post.

We all know INTV is just getting warmed up. It’s gonna get hot in here.

I would like to hear your opinion on it if you don’t mind.

Same same. This is going well over a dollar. My prediction is by June we all will be laughing to the bank.

I saw that. This is going to be a fun ride

The Bid is building nicely

Wow. What’s happening?

So why do public companies go private?

Being private frees up management’s time and effort to concentrate on running and growing a business with priority shifting from meeting quarterly earnings expectations to creating and building long-term shareholder wealth, as there are fewer regulations to comply with. Thus, the top management can focus more on improving the business’s competitive positioning in the marketplace.

Becoming and remaining private allows a more considerable degree of freedom for company management to embark on long-term, innovative, and higher risk ventures without the scrutiny of stock analysts, investors and the media, since the pressures of quarterly results do not bind a private company. Another reason for going private could be a buyout by a private company or a venture capitalist firm. By going private, the company’s shares will be delisted from the stock exchange and will no longer be traded in the exchange, so the company doesn’t have to deal with the volatility of the stock price. In return, the shareholders often get cash or stocks in a defined proportion.

Elon Musk had sent an email to Tesla employees and posted on its blog that the noise besieging Tesla is precisely why he wants to take its shares off the market, loosening up Tesla from some investor and media scrutiny in a year when it’s had some highly publicized struggles. “As a public company, we are subject to wild swings in our stock price that can be a major distraction for everyone working at Tesla,” he wrote. He also blamed the “quarterly earnings cycle,” which puts “enormous pressure on Tesla to make decisions that may be right for a given quarter, but not necessarily right for the long-term,” and a large number of short sellers “who have the incentive to attack the company.”

Also, as a private company undeterred by Wall Street’s 90-day attention span, it allowed Dell to boil down the priorities to just two metrics: cash flow and growth.

Source for above article

Yes i had to google why companies would go private over public. I understand why they go Public but never really understood why the other direction. I found this Article above and it helped break it down in a unbiased way for me. Maybe it will help with others as well.

It takes a while with Crayons.

looking forward to it. I have had a bad year for losses. Looking to right the ship.......

Who is doing all the selling? The Ask seems to be higher amounts than it was during its last run.

Whats the Chart say now?

Has anyone done any research on Medjet

"As of February 23, 2011. Medjet Inc. was acquired by For The Earth Corp. in a reverse merger transaction. Medjet Inc., through its subsidiary, The Earth Corporation, engages in the production and sale of green consumable household products primarily in Arizona. Its product line primarily comprises What Odor, a non toxic biodegradable product that removes odors; and PaPurr, a scoopable and non-clumping cat litter. The company sells its products to retail and industrial customers, including hotels, nursing homes, restaurants, and professional sports teams, as well as directly to consumers. Medjet Inc. was founded in 1993 and is based in Phoenix, Arizona."

And then i see a new CEO was named for Medjet in May 2018
Mike Hallman New CEO at Medjet Mike Hallman Named CEO that use to be ticker MDJT
MDJT becoms FTEG ticker

For the Earth Owns Medjet and also is doing Biodegradable Cleaning agents etc.

Something big is coming! In my Opinion i think it has to do with Medjet and the https://cleanlifecorp.com/
What are someone else thoughts on this?
$FTEG

Someone just bought that 10 Mil at .006. Amazing $60,000.00 Buy

Mary do you suppose the other option for cannabis is the Gro3 by AmFill?

Good thing about Elevators, they always go back up!

Oh good you are in this ticker too. Guess that is a BUY signal for sure. $INTV

I would say that $INTV would agree with you Doddi.

https://twitter.com/IntVentures/status/976941261147066370

I will be taking a position tomorrow, just because of this tweet.

New Tweet. "$EFLN Shareholders keep an eye out for big news sometime next week management is working hard"


If you havent followed them on twitter i suggest that you do. All/MOst of thier messages to shareholders will come through twitter.

Its On ETRADE. Lets go $ONCI the time is now.

How big was it?

Brought my average down today to .0186. Wish i could have added early this morning. Looks like there was some real impatient selling first thing to start the day. Lets see what tomorrow brings.
$ANDI $UTOP

Thank you for the Trifling reply.

Whether I end up being a bag holder or not is of my own accordance.
I do not buy because someone says buy the dip and surely would not sell because someone screams scam or POS.
My actions of buying is purely from my own DD and other research that has been brought to the board.

I imagine for some its hard to see the PPS drop like this. However i am actually excited for it. It allows me to add more bang for my buck. Having limited funds to play with, doesn't leave me with very many options except to be patient. I give myself about $200 per week to buy Andi shares.

I first bought in at .0295 and every few days or so i have noticed that it appears to be a group of people that are taking this price down. So I patiently wait until I see the price drop and then slap the ask. I have managed to average down to .0195.

I know its not a lot in comparison to some of the other shareholders here, but I see the potential of Utopya and believe that by the end of 2018 or maybe sooner my portfolio will look pretty damn good.

For every single share I buy is another share that gets locked away for my Daughters College Funds. And I have over 15 years to save up for that.

Good luck to everyone. $ANDI $UTOP

$OBMP therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients.

The PPS last year was .32 and is now under .016
Last year the company was only at Phase I and now they are in Phase II Trails.

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
https://www.otcmarkets.com/stock/OBMP/news/OncBioMune-Selects-Theradex-as-CRO-for-Two-Phase-2-Trials-of-ProscaVax-for-Prostate-Cancer?id=185610

ProscaVax – Prostate Cancer

"The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.

Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT02058680?term=oncbiomune&rank=1.

OvcaVax - Breast Cancer


We developed our vaccine in 1993 and then immediately began vaccinating patients with depressed immunity. We obtained the first patent on a breast cancer vaccine in the U.S.A. in 1994, and were the first to use the cytokines GM-CSF and IL-2 as biological adjuvants. Appropriate patients are vaccinated in the adjuvant setting and patients with advanced disease are treated with a combined chemo-immunotherapy protocol. Some of these patients have had dramatic responses.

Wow number 4 on the Breakout Boards.
Starting to get more eyes back on this.
$OBMP Looking Good so far what i see. I Still have a lot more DD to do, but i like what i see so far.

$OBMP current PPS .016 Volume increasing
This looks like it might have some great potential. Especially where the PPS was a year ago at .31 and that was only Phase I. They are now in Phase II with a CRO

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
https://www.otcmarkets.com/stock/OBMP/news/OncBioMune-Selects-Theradex-as-CRO-for-Two-Phase-2-Trials-of-ProscaVax-for-Prostate-Cancer?id=185610

ProscaVax – A Novel Prostate Cancer Vaccine

The Company has developed a therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment. The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.
The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination. During the trial the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients. We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically, it could become the standard of care for prostate cancer.
Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT02058680?term=oncbiomune&rank=1.

OvcaVax
Breast cancers and other epithelial malignancies are antigenic and elicit lymphocyte responses in the autologous host, and patients that express good host immunity to their tumor have better survival. Adequate host immunity is an independent prognostic indicator and those with poor immunity have shorter disease free intervals and shorter overall survival. The Company’s novel approach defines the tumor specific immune status of patients both pre and post immunotherapy that uses autologous tumor antigens to immunize patients. We have the ability to discriminate patients who are immunologically unreactive to tumor antigens and may be generally lymphocyte depressed from those who are tumor antigen reactive and lymphocyte competent. Thus those patients who are unreactive and in need of immunostimulation qualify for vaccination with specific tumor antigen .

We developed our vaccine in 1993 and then immediately began vaccinating patients with depressed immunity. We obtained the first patent on a breast cancer vaccine in the U.S.A. in 1994, and were the first to use the cytokines GM-CSF and IL-2 as biological adjuvants. Appropriate patients are vaccinated in the adjuvant setting and patients with advanced disease are treated with a combined chemo-immunotherapy protocol. Some of these patients have had dramatic responses.

The Company is presently devoting much research to the tumor stroma and microenvironment for a better understanding of tumor escape mechanisms. This will allow us the ability to better attack the tumor with specific adaptive immunotherapy. This work is in progress and early results are producing exciting results.

$OBMP current PPS .016 Volume increasing
This looks like it might have some great potential. Especially where the PPS was a year ago at .31 and that was only Phase I. They are now in Phase II with a CRO

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
https://www.otcmarkets.com/stock/OBMP/news/OncBioMune-Selects-Theradex-as-CRO-for-Two-Phase-2-Trials-of-ProscaVax-for-Prostate-Cancer?id=185610

ProscaVax – A Novel Prostate Cancer Vaccine

The Company has developed a therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients. It is tested and laboratory proven and could become the standard of care for prostate cancer treatment. The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.
The Company has data from a phase 1/2 clinical trial of their therapeutic prostate cancer vaccine. Patients with prostate cancer confirmed by biopsy and with an elevated PSA received the vaccine. We enrolled 12 patients in this study. All patients received their initial course of six vaccinations containing prostate specific antigen and biological adjuvant. Serum PSA concentrations were determined before initiating vaccination and 3-4 weeks after the 6th vaccination. Two-thirds of the prostate cancer patients’ PSAs decreased after vaccination. During the trial the prostate cancer patients received no other concurrent therapy (surgery, hormone, radiation, radioactive seeds, chemotherapy), and have additionally received three further vaccinations alternated with low dose IL-2 for the 6 months following the initial vaccinations. The Company developed the protocol for the vaccination of prostate cancer patients using techniques developed for vaccination of breast cancer patients. We are currently in a Phase 1 clinical trial at UCSD Medical School under an IND from the FDA with funding from the US Navy Cancer Vaccine Program. If proven effective clinically, it could become the standard of care for prostate cancer.
Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT02058680?term=oncbiomune&rank=1.

OvcaVax
Breast cancers and other epithelial malignancies are antigenic and elicit lymphocyte responses in the autologous host, and patients that express good host immunity to their tumor have better survival. Adequate host immunity is an independent prognostic indicator and those with poor immunity have shorter disease free intervals and shorter overall survival. The Company’s novel approach defines the tumor specific immune status of patients both pre and post immunotherapy that uses autologous tumor antigens to immunize patients. We have the ability to discriminate patients who are immunologically unreactive to tumor antigens and may be generally lymphocyte depressed from those who are tumor antigen reactive and lymphocyte competent. Thus those patients who are unreactive and in need of immunostimulation qualify for vaccination with specific tumor antigen .

We developed our vaccine in 1993 and then immediately began vaccinating patients with depressed immunity. We obtained the first patent on a breast cancer vaccine in the U.S.A. in 1994, and were the first to use the cytokines GM-CSF and IL-2 as biological adjuvants. Appropriate patients are vaccinated in the adjuvant setting and patients with advanced disease are treated with a combined chemo-immunotherapy protocol. Some of these patients have had dramatic responses.

The Company is presently devoting much research to the tumor stroma and microenvironment for a better understanding of tumor escape mechanisms. This will allow us the ability to better attack the tumor with specific adaptive immunotherapy. This work is in progress and early results are producing exciting results.